FREEHOLD, N.J., July 19, 2005 (PRIMEZONE) -- New Life Scientific (OTCBB:NWLF) and Invapharm LLC have announced that their collaborative effort “Invamed” has reached a significant corporate milestone of 50 percent patient recruitment in the Phase II study of a new delivery system in the treatment of patients with ulcerative colitis. The study expected to be completed in the fourth quarter of 2005 and the summary report available by the end of 2005.
